Clinical applications of newer radionuclide therapies

European Journal of Cancer

Volumn 42, Issue 8, 2006, Pages 994-1003

  Brans, Boudewijn ^a   Linden, Ola ^b   Giammarile, Francesco ^c   Tennvall, Jan ^b   Punt, Cornelis ^d  

^a Sittard Geleen Heerlen   (Netherlands)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c CENTRE LÉON BÉRARD   (France)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti CD20; Lipiodol; mIBG; Octreotide; Radioimmunotherapy; Radionuclide therapy; SIR spheres

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETAAZACYCLODODECANCE 1,4,7,10 TETRAACETIC ACID LANREOTIDE; 1,4,7,10 TETAAZACYCLODODECANCE 1,4,7,10 TETRAACETIC ACID LANREOTIDE YTTRIUM; 1,4,7,10 TETAAZACYCLODODECANCE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ACTINIUM 225; BISMUTH 213; BUSULFAN; CD20 ANTIBODY; CD33 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPRATUZUMAB; FLUOROURACIL; HUM 195; HYDROXYUREA; IBRITUMOMAB TIUXETAN; LUTETIUM 177; OCTREOTHER; OCTREOTIDE; ONCOLYM; PENTETATE INDIUM IN 111; PENTETIC ACID DERIVATIVE; PENTETREOTIDE; PENTETREOTIDE IN 111; PHOSPHORUS 32; RADIOISOTOPE; RITUXIMAB; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; TOPOTECAN; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADRENAL GLAND; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; DOSIMETRY; DRUG MEGADOSE; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; HYPERTHYROIDISM; LARGE CELL LYMPHOMA; LASER COAGULATION; LEUKEMIA; LIVER CANCER; LIVER METASTASIS; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MICROWAVE THERAPY; MORBIDITY; NEPHROTOXICITY; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NEUTROPHIL; ONCOLOGY; PHEOCHROMOCYTOMA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; RADIOFREQUENCY ABLATION; RADIOIMMUNOTHERAPY; SHORT SURVEY; SIDE EFFECT; STEM CELL TRANSPLANTATION; SYNOVITIS; THROMBOCYTE ANOMALY; THROMBOCYTHEMIA; THYROID CARCINOMA;

FORECASTING; HUMANS; NEOPLASMS; RADIOISOTOPES; RADIOTHERAPY;

EID: 33646396747     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.12.020     Document Type: Short Survey

References (77)

1. Behr T.M., Gotthardt M., Barth A., and Behe M. Imaging tumours with peptide-based radioligands. Q J Nucl Med 45 (2001) 189-200
2. Bombardieri E., Maccauro M., De Deckere E., Savelli G., and Chiti A. Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol 12 Suppl. 2 (2001) S51-S61
3. Breeman W.A., de Jong M., Kwekkeboom D.J., Valkema R., Bakker W.H., Kooij P.P., et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 28 (2001) 1421-1429
4. Pashankar F.D., O'Dorisio S., and Menda Y. MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use. J Nucl Med 46 (2005) 55S-61S
5. 131I-metaiodobenzylguanidine and high-dose chemotherapy with hematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transpl 27 (2001) 571-574
6. Matthay K.K., Panina C., Huberty J., Price D., Glidden D.V., Tang H.R., et al. Correlation of tumour and whole-body dosimetry with tumour response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 42 11 (2001) 1713-1721
7. Lashford L.S., Lewis I.J., Fielding S.L., Flower M.A., Meller S.T., Kemshead J.T., et al. Phase I/II study of iodine-131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 10 (1992) 1889-1896
8. DuBois S.G., Messina J., Maris J.M., Huberty J., Glidden D.V., Veatch J., et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 22 12 (2004) 2452-2460 June 15
9. Howard J.P., Maris J.M., Kersun L.S., Huberty J.P., Cheng S.C., Hawkins R.A., et al. Tumour response and toxicity with multiple infusions of high-dose 131I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer 44 3 (2005) 232-239
10. McCluskey A.G., Boyd M., Gaze M.N., and Mairs R.J. [(131)I]MIBG and topotecan: A rationale for combination therapy for neuroblastoma. Cancer Lett 1 (2005) 1 May 31
11. Gaze M.N., Chang Y.C., Flux G.D., Mairs R.J., Saran F.H., and Meller S.T. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 20 2 (2005) 195-199 April
12. Rose B., Matthay K.K., Price D., Huberty J., Klencke B., Norton J.A., et al. High-dose 131I-mIBG therapy for 12 patients with malignant phaeochromocytoma. Cancer 98 (2003) 239-248
13. Reubi J.C., Schar J.C., Waser B., Wenger S., Heppeler A., Schmitt J.S., et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 3 (2000) 273-282
14. Virgolini I., Traub T., Novotny C., Leimer M., Fuger B., Li S.R., et al. New trends in peptide receptors radioligands. Q J Nucl Med 45 (2001) 153-159
15. Valkema R., De Jong M., Bakker W.H., Breeman W.A., Kooij P.P., Lugtenburg P.J., et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2 (2002) 110-122
16. Anthony L.B., Woltering E.A., Espenan G.D., Cronin M.D., Maloney T.J., and McCarthy K.E. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2 (2002) 123-132
17. Otte A., Herrmann R., Heppeler A., Behe M., Jermann E., Powell P., et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 11 (1999) 1439-1447
18. Waldherr C., Pless M., Maecke H.R., Haldemann A., and Mueller-Brand J. The clinical value of [90Y-DOTA]-d-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 7 (2001) 941-945
19. Hejna M., Schmidinger M., and Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?. Ann Oncol 5 (2002) 653-668
20. Bodei L., Cremonesi M., Grana C., Rocca P., Bartolomei M., Chinol M., et al. Receptor radionuclide therapy with (90)Y-[DOTA](0)-Tyr(3)-octreotide ((90)Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imag 7 (2004) 1038-1046
21. Kwekkeboom D.J., Teunissen J.J., Bakker W.H., et al. Radiolabelled somatostatin analog (177Lu-DOTA, Tyr)Octreotate in patients with endocrine gastroenteropancreatic tumours. J Clin Oncol 23 (2005) 2754-2762
22. Kwekkeboom D., Mueller-Brand J., Paganelli G., et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabelled somatostatin analogs. J Nucl Med 46 (2005) 62S-66S
23. Pauwels S., Barone R., Walrand S., Borson-Chazot F., Valkema R., Kvols L.K., et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labelled somatostatin analogs. J Nucl Med 46 Suppl. 1 (2005) 92S-98S
24. Forster G.J., Engelbach M.J., Brockmann J.J., Reber H.J., Buchholz H.G., Macke H.R., et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide. Eur J Nucl Med 28 12 (2001) 1743-1750
25. Konijnenberg M.W., Bijster M., Krenning E.P., and De Jong M. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu. J Nucl Med 45 7 (2004) 1260-1269
26. Barone R., Borson-Chazot F., Valkema R., Walrand S., Chauvin F., Gogou L., et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 46 Suppl. 1 (2005) 99S-106S
27. Weiner R.E., and Thakur M.L. Radiolabelled peptides in oncology: role in diagnosis and treatment. BioDrugs 19 3 (2005) 145-163
28. Najean Y., and Rain J.D. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood 89 7 (1997) 2319-2327
29. Brandt L., and Anderson H. Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available?. Eur J Haematol 54 (1995) 21-26
30. Jurcic J.G. Immunotherapy for acute myeloid leukemia. Curr Oncol Rep 7 5 (2005) 339-346
31. Kaminski M.S., Tuck M., Estes J., Kolstad A., Ross C.W., Zasadny K., et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352 5 (2005) 441-449
32. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 4 (2002) 235-242
33. Witzig T.E., Gordon L.I., Cabanillas F., Czuczman M.S., Emmanouilides C., Joyce R., et al. Randomized controlled trial of yttrium-90-labelled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20 10 (2002) 2453-2463.36
34. Witzig T.E., Flinn I.W., Gordon L.I., Emmanouilides C., Czuczman M.S., Saleh M.N., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20 15 (2002) 3262-3269
35. Press O.W., Unger J.M., Braziel R.M., Maloney D.G., Miller T.P., LeBlanc M., et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 102 5 (2003) 1606-1612
36. Horning S.J., and Rosenberg S.A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311 23 (1984) 1471-1475
37. Johnson T.A., and Press O.W. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience. Ann Hematol 79 4 (2000) 175-182
38. Wahl R.L., Zasadny K.R., MacFarlane D., Francis I.R., Ross C.W., Estes J., et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med 39 Suppl. 8 (1998) 21S-27S
39. Koral K.F., Francis I.R., Kroll S., Zasadny K.R., Kaminski M.S., and Wahl R.L. Volume reduction versus radiation dose for tumours in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. Conjugate views compared with a hybrid method. Cancer 94 Suppl. 4 (2002) 1258-1263
40. Hindorf C., Linden O., Stenberg L., Tennvall J., and Strand S.E. Change in tumour-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients. Clin Cancer Res 9 10 Pt 2 (2003) 4003S-4006S
41. Hartmann Siantar C.L., DeNardo G.L., and DeNardo S.J. Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy. J Nucl Med 44 8 (2003) 1322-1329
42. Liu S.Y., Eary J.F., Petersdorf S.H., Martin P.J., Maloney D.G., Appelbaum F.R., et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labelled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 16 10 (1998) 3270-3278
43. Kaminski M.S., Zasadny K.R., Francis I.R., Fenner M.C., Ross C.W., Milik A.W., et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14 7 (1996) 1974-1981
44. Kaminski M.S., Estes J., Zasadny K.R., Francis I.R., Ross C.W., Tuck M., et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96 4 (2000) 1259-1266.17
45. Wahl R.L. Tositumomab and (131)I therapy in non-Hodgkin's lymphoma. J Nucl Med 46 Suppl. 1 (2005) 128S-140S
46. Morschhauser F, Huglo D, Martinelli D, Paganelli G, Zinzani P, Hadjiyiannakis D, et al. Yttrium-90 Ibritumomab Tiuxetan (Zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLCL). In: Ninth International Conference on Malignant Lymphoma; Lugano 2005.
47. Armitage JO, Leonard J, Gregory SA, Horning SA, Zelenetz A, Kaminski M, et al. The effectiveness of tositumomab and iodine I 131 tositumomab in relapsed/refractory follicular grade 1/2 and small lymphocytic non-Hodgkin's lymphoma (NHL). In: 2004 ASCO, Abstract 6573.
48. Gopal A.K., Rajendran J.G., Petersdorf S.H., Maloney D.G., Eary J.F., Wood B.L., et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99 9 (2002) 3158-3162
49. Press O.W., Eary J.F., Gooley T., Gopal A.K., Liu S., Rajendran J.G., et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96 9 (2000) 2934-2942
50. Nademanee A., Forman S., Molina A., Fung H., Smith D., Dagis A., et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106 8 (2005) 2896-2902
51. Coldwell D.M., and Sewell P.E. The expanding role of interventional radiology in the supportive care of the oncology patient: from diagnosis to therapy. Sem Oncol 32 (2005) 169-173
52. Tung-Ping-Poon R., Fan S.-T., Tsang F.H.-F., and Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeons's perspective. Ann Surg 4 (2002) 466-486
53. Bruix J., and Llovet J.M. Locoregional treatments for hepatocellular carcinoma. Bull Clin Gastroent 13 (1999) 611-622
54. Meyers M.O., Sasson A.R., and Sigurdson E.R. Locoregional strategies for colorectal hepatic metastases. Clin Colorectal Cancer 3 (2003) 34-44
55. Nijsen J.W.F., Zonnenberg B.A., Woittiez J.R.W., et al. Holmium-166 poly lactic acid microspheres applicable for intra-arterial radionuclide therapy of hepatic malignancies: effects of preparation and neutron activation techniques. Eur J Nucl Med 26 (1999) 699-704
56. Bretagne J.F., Raoul J.L., Bourguet P., et al. Hepatic artery injection of I-131-labelled lipiodol. Part II. Preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastases. Radiology 168 (1988) 547-550
57. Ho S., Lau W.Y., Leung T.W.T., and Johnson P.J. Internal radiation therapy for patients with primary or metastatic hepatic cancer: a review. Cancer 83 (1998) 1894-1907
58. De Baere T., Taourel P., Tubiana J.-M., et al. Hepatic intra-arterial I-131 iodized oil for treatment of hepatocellular carcinoma in patients with impeded portal venous flow. Radiology 212 (1999) 665-668
59. Risse J.H., Grunwald F., Kersjes W., et al. Intra-arterial HCC therapy with I-131-Lipiodol. Canc Bioth & Radiopharm 15 (2000) 65-70
60. Brans B., Van Laere K., Gemmel F., et al. Combining iodine-131 lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma. Eur J Nucl Med 29 (2002) 928-932
61. Raoul J.-L., Guyader D., Bretagne J.-F., et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis : intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 35 (1994) 1782-1787
62. Raoul J.-L., Guyader D., Bretagne J.-F., et al. Prospective randomized trial of chemoembolisation versus intra-arterial injection of I131-labelled-iodized oil in the treatment of hepatocellular carcinoma. Hepatol 26 (1997) 1156-1161
63. Lau W.Y., Leung T.W.T., Ho S.K.W., et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for respectable hepatocellular carcinoma: a prospective randomised trial. Lancet 353 (1999) 797-801
64. Partensky C., Sassolas G., Henry L., Paliard P., and Maddern G. Intra-arterial iodine 131-labelled Lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study. Arch Surg 135 (2000) 1298-1300
65. Boucher E., Corbinais S., Rolland Y., et al. Adjuvant intra-arterial injection of iodine-131-labelled lipiodol after resection of hepatocellular carcinoma. Hepatology 38 (2003) 1237-1241
66. Behr T.M., Liersch T., Griener-Bechert L., et al. Radio-immunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 94 Suppl. 4 (2002) 1373-1381
67. Brans B., De Winter F., Defreyne L., et al. The antitumoural activity of neoadjuvant intra-arterial I131-Lipiodol treatment for hepatocellular carcinoma: a pilot study. Cancer Biother & Radiopharm 16 (2001) 333-338
68. Raoul J.L., Messner M., Boucher E., Bretagne J.F., Campion J.P., and Boudjema K. Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of I131-labelled Lipiodol. Br J Surg 90 (2003) 1379-1383
69. Sundram F., Chau T.C., Onkhuudai P., Bernal P., and Padhy A.K. Preliminary results of transarterial rhenium-188 HDD Lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur J Nucl Med Mol Imag 31 (2004) 250-257
70. Lambert B., Bacher K., Defreyne L., et al. Re-188-HDD/Lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med 46 (2005) 60-66
71. Stubbs S., and Wickremesekera S.K. Selective internal radiation therapy (SIRT): a new modality for treating patients with colorectal liver metastases. HPB 6 (2004) 133-139
72. Murthy R., Nunez R., Sklaruk J., et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations and potential complications. Radiographics 25 (2005) S41-S55
73. Gray B., Van Hazel G., Hope M., et al. Randomised trial of SIR-spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases for primary large bowel cancer. Ann Oncol 12 (2001) 1711-1720
74. Van Hazel G., Blackwell A., Anderson J., et al. Randomized phase 2 trial of SIR-spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin alone in advanced colorectal cancer. J Surg Oncol 88 (2004) 78-85
75. Goldstein D., Van Hazel G., Pavlakis N., and Olver I. Selective Internal Radiation Therapy (SIRT) plus systemic chemotherapy with irinotecan. A phase I dose escalation study. J Clin Oncol 23 16S (2005) 3701
76. Van Hazel G., Price D., Bower G., Sharma R.A., Blanshard K., and Steward W.P. Selective internal radiation therapy (SIRT) for liver metastases with concomitant systemic oxaliplatin, 5-fluorouracil and folinic acid: a phase I/II dose escalation study. J Clin Oncol 23 16S (2005) 3657
77. Wong C.Y., Oing F., Savin M., et al. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolisation as evaluated by 18F fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol 16 (2005) 1101-1106